ArticlePediatric research2026
Standard versus restricted fluid administration in preterm infants undergoing pharmacological treatment for haemodynamically significant patent ductus arteriosus.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFluid management in patent ductus arteriosus (PDA) treatment is debated, with fluid restriction traditionally used to promote closure, though its impact on outcomes is uncertain.
methodsThis retro-prospective cohort single-center study compared two cohorts of preterm neonates receiving pharmacological treatment for hemodynamically significant PDA (hsPDA). The 2021-2023 cohort followed an updated, higher fluid intake protocol based on neonatal weight and day of life (80-100 ml/kg/day for extreme preterm <1000 g on day 1), while the 2018-2020 cohort adhered to a more restrictive approach based on gestational age and day of life (70 ml/kg/day for extreme preterm ≤26 weeks on day 1) and fluid restriction from 5 to 20% during pharmacological treatment of hsPDA. Outcomes included PDA closure rates, growth parameters, and neonatal complications.
resultshsPDA closure rates and major complications (intraventricular hemorrhage, necrotizing enterocolitis, or chronic lung disease) were similar between groups. However, fluid-restricted neonates required more central catheter days, longer times to full enteral feeding, and had poorer growth at discharge (lower weight z-scores).
conclusionsFluid restriction during pharmacological PDA treatment may adversely affect growth and clinical care without improving closure rates. A balanced, individualized fluid management strategy could enhance neonatal outcomes. IMPACT: The article suggests that fluid restriction does not improve the response to pharmacological treatment for PDA, but could negatively influence growth of preterm infants before discharge, which might have long term repercussions. It highlights there is no benefit, but potential harm, of fluid restriction to promote PDA in this vulnerable population. The findings could guide changes in clinical practice, improving PDA management and potentially reducing complications for preterm infants who are highly sensitive to fluid imbalances. The study advocates for further clinical trials to explore the optimal hydration strategies in managing PDA, paving the way for future research that can refine and standardize treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.